




Does antimicrobial prescribing correlate with bacterial coinfection in hospitalized COVID-19 patients?

Hospitalized COVID-19 patients often received empiric antibiotics for presumed bacterial respiratory coinfections



Outcomes of Interest

- Antimicrobial use**
 - Days of therapy (DOT) during COVID-19 surge (March-May 2020) vs. 2018 & 2019
- Respiratory bacterial coinfection**
 - Multidrug resistant (MDR)
 - Community acquired (≤ 3 days)
 - Hospital acquired (> 3 days)
- Clinical Outcomes**

Methods

Hospital admission between March 1st to May 31st 2020

Overall	Cultures
<ul style="list-style-type: none"> ICD-10 COVID-19 OR Positive SARS-CoV-2 nasopharyngeal PCR 	<ul style="list-style-type: none"> Respiratory Infection onset per CDC NHSN surveillance definition <ul style="list-style-type: none"> Community: ≤ 3 days Hospital: > 3 days

-Microbiologic and antimicrobial information taken from data repository
-Multidrug-resistant Gram-negative rods (MDR GNR) per CDC NHSN definition


Outcomes of Interest

- Descriptive**
- Demographics
 - Antimicrobial days of therapy (DOT) compared to previous years
 - Organism(s) isolated
- Sub-Analysis**
- Case-control
 - MDR GNR vs. other respiratory pathogens
 - Antimicrobial exposure, odds ratio


Results

Demographics n=829

- Sex, male n (%): **410 (49.5)**
- Age, years, mean (SD): **64.9 (± 17.9)**
- Hospital admission in the last 90 days, n (%): **112 (13.5)**



Underlying Comorbidities




Clinical Outcomes

- Median length of stay, days (IQR): **6 (2-13)**
- Inpatient mortality/discharge to hospice, n (%): **171 (20.6)**
- C. difficile* PCR positive during hospitalization, n (%): **29 (3.5)**

Microorganisms isolated from respiratory samples

- Patients with positive respiratory cultures: 196 (23.6%)



Results (continued)

Antimicrobial Exposure During Hospitalization n=829


73% were prescribed antibiotics against respiratory pathogens

- 33%** prescribed ceftriaxone
- 22%** prescribed antipseudomonal beta-lactams
- 21%** prescribed vancomycin or linezolid
- 21%** prescribed azithromycin





Antimicrobial Utilization

March-May: 2018 vs 2019 vs 2020





DOT by Specific Antimicrobial Agent





Resistance in Pseudomonas spp. (n=30) and Enterobacteriales (n=50)



Case-Control Sub-Analysis

Population: hospitalized patients with organisms isolated in respiratory samples



Cases (n=30)

- COVID-19 positive
- MDR GNR in respiratory samples


Controls (n=96)

- COVID-19 positive and negative
- Other respiratory pathogens

GNR-Directed Antibiotic Exposures



Each antibiotic day



↑6.5% Risk MDR GNR



(OR 1.065 [1.003-1.131])

Discussion

- Bacterial coinfection is uncommon upon presentation
- Antibiotic usage and DOT was substantially increased compared to prior years during the study period
- Each day of antibiotic use was associated with a 6.5% increased risk of MDR GNR isolation

Strengths and Limitations

- Large sample size
- Longitudinal DOT assessment
- Case-control sub-analysis
- Infection versus colonization
- Confounding by indication
- Survival bias

Future Direction

- 🔍 Investigate the utility of rapid diagnostics for decision support
- 👥 Develop targeted interventions to limit antibiotic usage
- 🏥 Compare MDR GNR isolation with other institutions